[HTML][HTML] Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics

Y Gupta, OV Savytskyi, M Coban, A Venugopal… - Molecular Aspects of …, 2023 - Elsevier
With more than 5 million fatalities and close to 300 million reported cases, COVID-19 is the
first documented pandemic due to a coronavirus that continues to be a major health …

How to use COVID-19 antiviral drugs in patients with chronic kidney disease

A Kale, V Shelke, N Dagar, HJ Anders… - Frontiers in …, 2023 - frontiersin.org
Antiviral drugs such as Remdesivir (Veklury), Nirmatrelvir with Ritonavir (Paxlovid),
Azvudine, and Molnupiravir (Lagevrio) can reduce the risk for severe and fatal Coronavirus …

COVID‐19: An Overview of SARS‐CoV‐2 Variants—The Current Vaccines and Drug Development

N Bostanghadiri, P Ziaeefar, MG Mofrad… - BioMed Research …, 2023 - Wiley Online Library
The world is presently in crisis facing an outbreak of a health‐threatening microorganism
known as COVID‐19, responsible for causing uncommon viral pneumonia in humans. The …

[HTML][HTML] Fuzzy logical algebra and study of the effectiveness of medications for COVID-19

S Khalil, A Hassan, H Alaskar, W Khan, A Hussain - Mathematics, 2021 - mdpi.com
A fuzzy logical algebra has diverse applications in various domains such as engineering,
economics, environment, medicine, and so on. However, the existing techniques in algebra …

Recent advances in small-molecular therapeutics for COVID-19

L Zhong, Z Zhao, X Peng, J Zou… - Precision Clinical …, 2022 - academic.oup.com
The COVID-19 pandemic poses a fundamental challenge to global health. Since the
outbreak of SARS-CoV-2, great efforts have been made to identify antiviral strategies and …

Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 Mpro, Impairing Variants Replication In Vitro and In Vivo

OA Chaves, CQ Sacramento, AC Ferreira, M Mattos… - Pharmaceuticals, 2021 - mdpi.com
Atazanavir (ATV) has already been considered as a potential repurposing drug to 2019
coronavirus disease (COVID-19); however, there are controversial reports on its mechanism …

Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically …

D Battaglini, F Cruz, C Robba, P Pelosi… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction The coronavirus disease 2019 (COVID-19) pandemic has put a strain on global
healthcare systems. Despite admirable efforts to develop rapidly new pharmacotherapies …

Molecular insights of SARS-CoV-2 antivirals Administration: a balance between Safety profiles and Impact on Cardiovascular phenotypes

F Nappi, A Iervolino, SS Avtaar Singh - Biomedicines, 2022 - mdpi.com
The COVID-19 pandemic has resulted in a complex clinical challenge, caused by a novel
coronavirus, partially similar to previously known coronaviruses but with a different pattern of …

Drugs repurposing for SARS-CoV-2: New insight of COVID-19 druggability

SK Debnath, M Debnath, R Srivastava… - Expert Review of Anti …, 2022 - Taylor & Francis
Introduction The ongoing epidemic of severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) creates a massive panic worldwide due to the absence of effective …